Berman Capital Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Berman Capital Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$0	Buy	+9	New	+$299	﹤0.01%	2173

Other funds holding PHAT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Berman Capital Advisors's PHAT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Phathom Pharmaceuticals (PHAT) in Q3 2021: 9 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2173 among its holdings.

84 funds tracked by Wall St. Rank hold PHAT as of Q3 2021.

Berman Capital Advisors held 9 shares of Phathom Pharmaceuticals worth $0 as of Q3 2021.
Phathom Pharmaceuticals was a new Berman Capital Advisors position in Q3 2021.
Phathom Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2173 holding.
84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.